Support: 888-992-3836 Home NewsWire Subscriptions
InvestorsHub Logo
Login/Register
OCEL
Organicell Regenerative Medicine Inc.
82
Follow
82
OCEL
Organicell Regenerative Medicine Inc.
82
Follow
82
Likes Subject
Older
Ba s tards taking it back. Faked me backtoreality 05/23/23 5:54 PM
It sure seems like we are basing at backtoreality 05/17/23 11:32 AM
That's because of them getting that slap on backtoreality 04/25/23 11:12 AM
It’s interesting as there is absolutely no news. BLUEVOODU 04/25/23 11:04 AM
I'd keep cash on hand and keep an backtoreality 04/25/23 9:57 AM
It’s tempting to buy more. But there’s absolutely BLUEVOODU 04/24/23 7:09 PM
Bottom in? backtoreality 04/12/23 7:36 PM
I'm seeing more energy in otc plays. backtoreality 03/21/23 4:12 PM
Let's see where we are end of week.. backtoreality 03/20/23 5:13 PM
Is the bottom in? backtoreality 03/20/23 3:55 PM
Is the Bottom in. TIME WILL TELL backtoreality 03/13/23 2:55 PM
Why invest here on speculation of what may backtoreality 03/06/23 2:50 PM
Why invest here on speculation of what may backtoreality 03/06/23 2:30 PM
So who is selling? The company or backtoreality 03/06/23 2:27 PM
WEIRD, my tos is showing a ridiculous pop bude 03/04/23 8:27 AM
The trial will not be totally enrolled until backtoreality 02/28/23 12:59 PM
Dropped to near $0.01 today. BLUEVOODU 02/28/23 10:29 AM
I should of known I bought to soon backtoreality 02/18/23 9:29 AM
So did my other long term covid play. backtoreality 02/15/23 7:32 PM
Thank you for checking into that. Been a BLUEVOODU 02/15/23 2:42 PM
Isn't there a filing due? backtoreality 02/15/23 9:37 AM
Is this the "bottom" time to buy time? backtoreality 02/14/23 6:47 PM
So Zofin trial status "recruiting". On clinical trials.gov backtoreality 02/12/23 11:12 AM
I don't have any news. I didn't think backtoreality 02/12/23 11:00 AM
I haven’t been able to find anything. The BLUEVOODU 02/11/23 7:43 PM
I think there will be more buying opportunities backtoreality 02/09/23 12:16 PM
I sold a bunch after they got that backtoreality 12/15/22 10:36 AM
Starting to wonder if I missed an opportunity BLUEVOODU 12/14/22 11:05 AM
I'm still holding my shares. I BLUEVOODU 12/13/22 1:11 PM
I don't see any more sales than what BLUEVOODU 12/12/22 5:50 PM
I call crashing the stock price selling out backtoreality 12/12/22 9:39 AM
Is there still a product though? this BLUEVOODU 12/12/22 9:06 AM
The greedy assholes running this shit show have backtoreality 12/10/22 12:52 PM
Toast. Happy Holidays Ocel investors. I knew backtoreality 12/10/22 12:46 PM
Anyone think this guy who left was involved backtoreality 11/25/22 12:23 PM
Lol, tell us how you really feel?! backtoreality 11/23/22 8:28 AM
Lol! Hell no! I hate I wedman 11/22/22 9:48 PM
Love,,, your "Fav quote" miss Wedman. backtoreality 11/22/22 4:34 PM
Agree !! I have always been in it wedman 11/22/22 4:16 PM
Well it would at least show that they backtoreality 11/22/22 4:14 PM
Would like to see insiders buying this at wedman 11/22/22 3:21 PM
I didn't even see the PR until Blu backtoreality 11/22/22 2:05 PM
I don’t think so based on that p wedman 11/22/22 1:58 PM
Think they'll stick them with the CE designation? backtoreality 11/22/22 1:54 PM
Sounds like he is being honest but he wedman 11/22/22 1:37 PM
I think this is a different situation then backtoreality 11/22/22 1:34 PM
https://marketwirenews.com/news-releases/organicell-regenerative-medicine-inc-re wedman 11/22/22 1:30 PM
Insiders dumped yesterday. If this is what backtoreality 11/22/22 1:20 PM
Wondered why there was a near 50% drop: BLUEVOODU 11/22/22 12:30 PM
Wrong tthe Organicell drug trial is for people backtoreality 11/20/22 10:21 AM
Likes Subject
Older

Older
backtoreality
05/23/23 5:54 PM
backtoreality
05/17/23 11:32 AM
backtoreality
04/25/23 11:12 AM
BLUEVOODU
04/25/23 11:04 AM
backtoreality
04/25/23 9:57 AM
BLUEVOODU
04/24/23 7:09 PM
backtoreality
04/12/23 7:36 PM
backtoreality
03/21/23 4:12 PM
backtoreality
03/20/23 5:13 PM
backtoreality
03/20/23 3:55 PM
backtoreality
03/13/23 2:55 PM
backtoreality
03/06/23 2:50 PM
backtoreality
03/06/23 2:30 PM
backtoreality
03/06/23 2:27 PM
bude
03/04/23 8:27 AM
backtoreality
02/28/23 12:59 PM
BLUEVOODU
02/28/23 10:29 AM
backtoreality
02/18/23 9:29 AM
backtoreality
02/15/23 7:32 PM
BLUEVOODU
02/15/23 2:42 PM
backtoreality
02/15/23 9:37 AM
backtoreality
02/14/23 6:47 PM
backtoreality
02/12/23 11:12 AM
backtoreality
02/12/23 11:00 AM
BLUEVOODU
02/11/23 7:43 PM
backtoreality
02/09/23 12:16 PM
backtoreality
12/15/22 10:36 AM
BLUEVOODU
12/14/22 11:05 AM
BLUEVOODU
12/13/22 1:11 PM
BLUEVOODU
12/12/22 5:50 PM
backtoreality
12/12/22 9:39 AM
BLUEVOODU
12/12/22 9:06 AM
backtoreality
12/10/22 12:52 PM
backtoreality
12/10/22 12:46 PM
backtoreality
11/25/22 12:23 PM
backtoreality
11/23/22 8:28 AM
wedman
11/22/22 9:48 PM
backtoreality
11/22/22 4:34 PM
wedman
11/22/22 4:16 PM
backtoreality
11/22/22 4:14 PM
wedman
11/22/22 3:21 PM
backtoreality
11/22/22 2:05 PM
wedman
11/22/22 1:58 PM
backtoreality
11/22/22 1:54 PM
wedman
11/22/22 1:37 PM
backtoreality
11/22/22 1:34 PM
wedman
11/22/22 1:30 PM
backtoreality
11/22/22 1:20 PM
BLUEVOODU
11/22/22 12:30 PM
backtoreality
11/20/22 10:21 AM

Organicell Regenerative Medicine Inc. (OCEL)

Followers
82
Posters
224
Posts (Today)
0
Posts (Total)
1954
Created
07/10/15
Type
Free
Moderators
Authorized Shares 
2,500,000,000 
04/09/2021 
Outstanding Shares 
1,041,341,874 
04/09/2021 
Restricted 
847,212,409 
04/09/2021 
Unrestricted 
194,129,465 
04/09/2021

Published: Apr 28, 2021  

https://www.biospace.com/article/releases/organicell-announces-positive-results-of-initial-covid-19-zofin-patient-trial-in-india-and-trial-expansion 

MIAMI--(BUSINESS WIRE)-- Organicell Regenerative Medicine, Inc. (OTCMKTS: BPSR), a clinical-stage biopharmaceutical company dedicated to the development of regenerative therapies, today announced positive results for the first ten COVID-19 patients treated with Zofin™ in India. This initial trial is being conducted in conjunction with Organicell's Indian partner, CWI India, with whom Organicell entered into a product testing and distribution agreement on February 9, 2021 to study the effects of Zofin™ on moderate to severe COVID-19 patients.  

The initial ten trial participants were hospitalized patients and were treated at Narayana Hrudayalaya Hospital in Bangalore, Lisa Hospital in Kozhikode, Kerala and Prime Indian Hospital in Chennai, and all patients have recovered from their symptoms and have since been discharged from the hospital. Based on the initial results of this trial, the trial will be expanded to an additional sixty-five patients with moderate to severe COVID-19, who will be treated at these hospitals over the next several weeks, with treatments expected to be completed by the end of June 2021.  

If the results of the expanded trial are similarly positive, Organicell and CWI India, intend to file with the ICMR (Indian Council for Medical Research) for Emergency Use Approval to use Zofin™ in India as a therapeutic for treating COVID-19.  

The Indian Health Ministry is reporting more than 350,000 new COVID infections and over 2,500 deaths per day, a world record, and India is now seeing more new infections than any other country, almost half of all new cases in a global surge.  

“The explosive spread of COVID-19 in India, and the lack of treatment that is available to help these millions of people is quite alarming and tragic. We are hopeful that Zofin™ can continue to help these patients, and we will do everything we can to expedite this process,” said Albert Mitrani, CEO of Organicell.  

“We are very encouraged with the results shown by patients using Zofin™ and are hopeful that the remaining trial patients will show similar results. These trials could set the stage for a very quick Emergency Use Approval to be able to use Zofin™ for all of our patients,” said Doctor Matthew Roshan of CWI India.  

About Zofin™:  

Zofin™ is an acellular biologic therapeutic derived from perinatal sources and is manufactured to retain naturally occurring microRNAs, without the addition or combination of any other substance or diluent. This product contains over 300 growth factors, cytokines, and chemokines as well as other extracellular vesicles/nanoparticles derived from perinatal tissues. Zofin™ is currently being tested in a phase I/II randomized, double blinded, placebo trial to evaluate the safety and potential efficacy of intravenous infusion of Zofin™ for the treatment of moderate to SARS related to COVID-19 infection vs placebo.  

ABOUT ORGANICELL REGENERATIVE MEDICINE, INC.  

Organicell Regenerative Medicine, Inc. (OTCMKTS: BPSR) is a clinical-stage biopharmaceutical company that harnesses the power of exosomes to develop innovative biological therapeutics for the treatment of degenerative diseases. The Company’s proprietary products are derived from perinatal sources and manufactured to retain the naturally occurring exosomes, hyaluronic acid, and proteins without the addition or combination of any other substance or diluent. Based in South Florida, the company was founded in 2008 by Albert Mitrani, Chief Executive Officer and Dr. Mari Mitrani, Chief Scientific Officer. To learn more, please visit https://organicell.com/.  

FORWARD-LOOKING STATEMENTS  

Certain of the statements contained in this press release should be considered forward-looking statements within the meaning of the Securities Act of 1933, as amended (the “Securities Act”), the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and the Private Securities Litigation Reform Act of 1995. These forward-looking statements are often identified by the use of forward-looking terminology such as “will,” “believes,” “expects,” “potential” or similar expressions, involving known and unknown risks and uncertainties. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, they do involve assumptions, risks and uncertainties, and these expectations may prove to be incorrect. We remind you that actual results could vary dramatically as a result of known and unknown risks and uncertainties, including but not limited to: potential issues related to our financial condition, competition, the ability to retain key personnel, product safety, efficacy and acceptance, the commercial success of any new products or technologies, success of clinical programs, ability to retain key customers, our inability to expand sales and distribution channels, legislation or regulations affecting our operations including product pricing, reimbursement or access, the ability to protect our patents and other intellectual property both domestically and internationally and other known and unknown risks and uncertainties, including the risk factors discussed in the Company’s periodic reports that are filed with the SEC and available on the SEC’s website (http://www.sec.gov). You are cautioned not to place undue reliance on these forward-looking statements All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these risk factors. Specific information included in this press release may change over time and may or may not be accurate after the date of the release. Organicell has no intention and specifically disclaims any duty to update the information in this press release.  



View source version on businesswire.com: https://www.businesswire.com/news/home/20210428005214/en/ 

Contacts  

Jeffrey Freedman  
RooneyPartners  
646-432-0191  
jfreedman@rooneyco.com  



Source: Organicell Regenerative Medicine, Inc.  

Powered by Business Wire  
View this news release online at:  
http://www.businesswire.com/news/home/20210428005214/en
Most Liked Posts
(Last 30 Days)
Volume:
Day Range:
Last Trade Time:
Upgrade to Real-Time
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Detailed Quote
Detailed Quote
OCEL Latest News
More OCEL News
Most Liked Posts
(Last 30 Days)
New Post